相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
Alexander Hoellein et al.
Oncotarget (2015)
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A. R. Abdul Razak et al.
ANNALS OF ONCOLOGY (2013)
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study
J. K. Lee et al.
ANNALS OF ONCOLOGY (2013)
Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
Alexis B. Cortot et al.
CANCER RESEARCH (2013)
Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells
Kazuhiko Shien et al.
CANCER RESEARCH (2013)
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy
Paul Yeh et al.
CLINICAL CANCER RESEARCH (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma
Carol Box et al.
EUROPEAN JOURNAL OF CANCER (2013)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease
Kadoaki Ohashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
Geoffrey R. Oxnard et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
Hideki Terai et al.
MOLECULAR CANCER RESEARCH (2013)
EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
Maria E. Arcila et al.
MOLECULAR CANCER THERAPEUTICS (2013)
High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases-One with a remarkable thoracic response as well
J. L. Kuiper et al.
LUNG CANCER (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
The Role of MET Receptor Tyrosine Kinase in Non-Small Cell Lung Cancer and Clinical Development of Targeted Anti-MET Agents
Kyle W. Robinson et al.
ONCOLOGIST (2013)
Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Hong-bing Liu et al.
PLOS ONE (2013)
PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis
Gregory R. Bean et al.
SCIENCE SIGNALING (2013)
Noncovalent Wild-type-Sparing Inhibitors of EGFR T790M
Ho-June Lee et al.
CANCER DISCOVERY (2013)
Maximizing the Benefits of Off-Target Kinase Inhibitor Activity
Monica Red Brewer et al.
CANCER DISCOVERY (2013)
A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
K. E. Ware et al.
ONCOGENESIS (2013)
NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma
Tomoya Yamaguchi et al.
CANCER CELL (2012)
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
Carolina Navas et al.
CANCER CELL (2012)
EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
Christine M. Ardito et al.
CANCER CELL (2012)
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation
Daijiro Harada et al.
CANCER SCIENCE (2012)
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Sidong Huang et al.
CELL (2012)
Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance
Takenori Ogawa et al.
CELL CYCLE (2012)
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
Mai He et al.
CLINICAL CANCER RESEARCH (2012)
Clinical Outcomes in Non-Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR
Kuei-Pin Chung et al.
CLINICAL CANCER RESEARCH (2012)
Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?
N. R. Budha et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
Sai-Hong Ignatius Ou
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
Francois Guilhot et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
Andrew J. Weickhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Challenge and Promise of the Genomic Era
George W. Sledge
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
Pasi A. Jaenne et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer
Jasmine Foo et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping
Geoffrey R. Oxnard et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer
Rodrigo Dienstmann et al.
MOLECULAR ONCOLOGY (2012)
Conversion from the oncogene addiction to drug addiction by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation
Kenichi Suda et al.
LUNG CANCER (2012)
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials
Fausto Petrelli et al.
LUNG CANCER (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair
Xue Zhang et al.
NATURE GENETICS (2012)
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
Michela Garofalo et al.
NATURE MEDICINE (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
King Pan Ng et al.
NATURE MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
Zhi-Yong Chen et al.
ONCOLOGIST (2012)
A CD44high/EGFRlow Subpopulation within Head and Neck Cancer Cell Lines Shows an Epithelial-Mesenchymal Transition Phenotype and Resistance to Treatment
Linnea La Fleur et al.
PLOS ONE (2012)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Kadoaki Ohashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
Tim Forshew et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
Levi A. Garraway et al.
CANCER DISCOVERY (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
Managing drug resistance in cancer: lessons from HIV therapy
Christoph Bock et al.
NATURE REVIEWS CANCER (2012)
Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis
Alessandra Gentile et al.
CANCER RESEARCH (2011)
HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
David Liska et al.
CLINICAL CANCER RESEARCH (2011)
Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2011)
Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
Yelena Y. Janjigian et al.
CLINICAL CANCER RESEARCH (2011)
Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer
Jenn-Yu Wu et al.
CLINICAL CANCER RESEARCH (2011)
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
Jamie E. Chaft et al.
CLINICAL CANCER RESEARCH (2011)
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A. Becker et al.
EUROPEAN JOURNAL OF CANCER (2011)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma
Yasushi Yatabe et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations
Young-Woong Won et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice
Leina Sun et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)
Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib
Melissa L. Johnson et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Liposomal Delivery of MicroRNA-7-Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells
Kammei Rai et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
Roy S. Herbst et al.
LANCET (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Trever G. Bivona et al.
NATURE (2011)
Drug-Induced Effects on Erlotinib Metabolism
Olivier Mir et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib
Vince D. Cataldo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer
Eunice Kwak
ONCOLOGIST (2011)
Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells
Carmen Holz et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Scott C. Bresler et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
Juliann Chmielecki et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers
Hiu Wing Cheung et al.
CANCER DISCOVERY (2011)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies
Michael Campoli et al.
CLINICAL CANCER RESEARCH (2010)
Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor-Mutant Lung Cancer
Juliann Chmielecki et al.
CLINICAL CANCER RESEARCH (2010)
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
Kenichi Suda et al.
CLINICAL CANCER RESEARCH (2010)
Small-Cell Carcinoma With an Epidermal Growth Factor Receptor Mutation in a Never-Smoker With Gefitinib-Responsive Adenocarcinoma of the Lung
Naheed Alam et al.
CLINICAL LUNG CANCER (2010)
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
Tetsuya Mitsudomi et al.
FEBS JOURNAL (2010)
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: It Does Not Always Fade With Time
Jean-Yves Douillard
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer-Associated Fibroblasts Derived from EGFR-TKI-Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs
Sheldon R. Mink et al.
MOLECULAR CANCER RESEARCH (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Understanding resistance to EGFR inhibitors-impact on future treatment strategies
Deric L. Wheeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
D. Ercan et al.
ONCOGENE (2010)
Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
Kathryn E. Ware et al.
PLoS One (2010)
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Zhan Yao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L. Sos et al.
CANCER RESEARCH (2009)
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2009)
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
George N. Naumov et al.
CLINICAL CANCER RESEARCH (2009)
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer
Yanan Kuang et al.
CLINICAL CANCER RESEARCH (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer
Thomas J. Lynch et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
Sarah Park et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Andrea Sartore-Bianchi et al.
PLOS ONE (2009)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Richard A. Larson et al.
BLOOD (2008)
Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib
Kazuya Taniguchi et al.
CANCER SCIENCE (2008)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The T790M gatekeeper mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor
Nadia Godin-Heymann et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Detection of mutations in EGFR in circulating lung-cancer cells
Shyamala Maheswaran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
Tetsuya Mitsudomi et al.
CANCER SCIENCE (2007)
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the Anti-EGFR monoclonal antibody cetuximab
Yang Lu et al.
CANCER RESEARCH (2007)
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study
Fumiko Taguchi et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
Cai-Hong Yun et al.
CANCER CELL (2007)
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus
Gregory J. Riely et al.
CLINICAL CANCER RESEARCH (2007)
Molecular on/off switch
Daniel T. Milton et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
John C. Sok et al.
CLINICAL CANCER RESEARCH (2006)
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
Michio Inukai et al.
CANCER RESEARCH (2006)
EGFR mutations in small-cell lung cancers in patients who have never smoked
MF Zakowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Bin-Bing S. Zhou et al.
CANCER CELL (2006)
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
Shizhen Emily Wang et al.
CANCER CELL (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
GJ Riely et al.
CLINICAL CANCER RESEARCH (2006)
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
DW Bell et al.
NATURE GENETICS (2005)
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
H Greulich et al.
PLOS MEDICINE (2005)
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition
S Thomson et al.
CANCER RESEARCH (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
EL Kwak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy
A Gschwind et al.
NATURE REVIEWS CANCER (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
分享论文
